Smoking Cessation Drugs Market Overview
Smoking cessation drugs are de-addiction drugs for smoking. The alkaloid compound called nicotine causes addictive dependency on cigarettes and other smoking products. Smoking cessation results in withdrawal symptoms such as anxiety, strong cravings, depressing mood, insomnia and mood alterations.
According to the World Health Organization (WHO), over 6 millions premature deaths occur every year due to tobacco-related disease and estimated to rise up to 8 million by 2030, with over 80% of deaths from developing countries.
Tobacco smoking contain more than 7000 hazardous compounds that cause or aggravate the pre-existing diseases including diabetes, weaker immunity, respiratory diseases and lungs cancer, cardiovascular complications, cataract, macular degeneration, eyesight loss, impotency or infertility and tooth or gum diseases.
Smoking addiction is diagnosed with the Fagerstro¨m Test for Nicotine Dependence (FTND). The global smoking cessation drugs market is fuelled by the escalating numbers of smokers, smoking related-respiratory diseases, rising awareness of smoking cessation drugs and prohibition of public smoking.
Coronavirus has been instrumental in elevating the smoking cessation drugs market growth with the surge seen in the smoking quitters and non-availability of smoking products.
The research and observation in Coronavirus pathogenesis have concluded that smoking aggravates the respiratory fatalities, and weakens the immune system leading to hospitalization, permanent respiratory and cardiovascular damages, and deaths. These findings are pushing the numbers of smoking-quitters and boosting the sales of smoking cessations drugs.
Smoking Cessation Drugs Market: Drivers and Restraints
The drivers of global smoking cessation drugs market include surging respiratory diseases due to the increasing smoking addiction, governments and organization’s anti-smoking initiatives and campaigns.
The reimbursements policies for smoking cessation drug therapies, anti-smoking programs by WHO such as ‘Tobacco Free Initiative’, increasing consciousness and educations among young population and smokers, and the approved smoking cessation drugs in the market are leveraging smoking cessation drugs market.
The key players of smoking cessation drugs are working with the prime motive to develop novel smoking cessation drugs for effective smoking cessations with lesser chance of relapse. However, there are certain restraints of smoking cessation drugs market that decelerates its growth.
The high cost of smoking cessation drugs, adverse reactions, smoking-relapse, lack of mass acceptance, less awareness of smoking cessation drugs are hampering the smoking cessation drugs market growth. Although, the overall smoking cessation drugs market is anticipated to grow further with the elevating smoking addictions and its associated respiratory diseases.
The availability of diverse smoking cessation drugs, rising awareness, medical regulations, government's aid, awareness for smoking cessation drugs therapies are expected to rocket the smoking cessation drugs market growth.
Smoking Cessation Drugs Market: Overview
The global smoking cessation drugs market is growing lucratively with the increasing smoking addictions, high prevalence of smoking-associated diseases and anti-smoking campaigns promoting the smoking cessation drugs.
By-products, nicotine replacement therapy (NRT) dominates the smoking cessation drugs product type with the attribution of NRT’s efficacy of smoking cessation and availability of a wide variety of FDA approved NRT gum, patches, inhalers and sprays.
By distribution channels, hospital pharmacies lead the smoking cessation drugs distributions with their advanced diagnostic and medication, trained staffs, monitoring and services, government’s collaboration and reimbursements.
Smoking Cessation Drugs Market: Pipeline Analysis
The developing smoking cessation drugs and vaccines target nAChRs, monoamine oxidase B (MAOB), cannabinoid receptor 1 (CB1R) and dopamine D3 receptor (DRD3). Tabex (cytisine) by Sopharma/Extabhave targets nAChR partial agonist is currently at phase III. A range of smoking cessation drugs in the pipeline includes NAL2762, MK0364, Selegiline, Meclizine, D-cycloserine and GSK598809.
The novel smoking cessation drugs include vaccination against nicotine, wherein vaccine-induced antibodies bind nAChRs and halt its movement to the brain. NicVAX (Nabi Biopharmaceuticals/GSK), NIC-002 (Cytos, Phase II) TA-NIC (Celtic Pharmaceuticals) and Niccine (Independent Pharmaceutica) are such vaccines for in clinical trials.
Smoking cessation vaccines emerge as a multifaceted therapy with or without conjunction with smoking cessation drugs and behavioural interventions.
Smoking Cessation Drugs Market: Regional Outlook
North America leads the global smoking cessation drugs market with major attributions by its advanced healthcare, massive use of smoking cessation drugs among teenager and adult smokers and increasing disposable income.
Europe holds the second largest global smoking cessation drugs market with the increasing smoking addictions, anti-smoking campaigns and a wide range of smoking cessation drugs. Asia-pacific smoking cessation drugs market is experiencing lucrative growth driven by its progressing economy, regional business expansions, market opportunities, large pool of smokers and anti-smoking campaigns.
Latin America smoking cessation drugs market is escalating with the increasing addictions and anti-smoking campaigns supporting the smoking cessation drugs usage. MEA &Africa smoking cessation drugs market is growing moderately due to the increasing smoking addictions.
Smoking Cessation Drugs Market: Key Players
The key players of smoking cessation drugs market include
- Dr Reddy's Laboratories
- Johnson & Johnson
- Fontem Ventures
- Huizhou Kimree Technology Co.Ltd.
- NovartisNjoy Inc
- Perrigo and Reynolds American Inc.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report covers exhaust analysis on
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Europe (Germany, U.K, France, Italy, Spain)
- South Asia (India, ASEAN Countries)
- East Asia (Japan, China & South Korea)
- Oceania (Australia & New Zealand)
- Middle East and Africa (GCC Countries, South Africa, Northern Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Smoking Cessation Drugs Market: Segmentation
The global smoking cessation drugs market is segmented into products, distribution channels and regions.
- Non nicotine drugs (Zyban, Chantix, Nicorette Buccal)
- Nicotine Replacement Therapy (NRT) (Gum, Patches, Lozenges, Inhalers, Sprays)
By Distribution Channels :
- Hospital Pharmacies
- Retailer Pharmacies
- Online Pharmacies